Johnson & Johnson’s latest earnings bested Wall Street estimates, as the company braces for one of its top-selling medicines ...

The Wall Street Journal editorial board tore into President Donald Trump for pardoning the rioters who attacked the Capitol ...

Johnson & Johnson (JNJ) beat on fourth quarter and full-year 2024 results, but its stock traded down on Wednesday morning to ...

Wall Street's Greatest Dividend Stock -- a Small-Cap Company 99% of Investors Have Never Heard of -- Is the Cheapest It's ...

Johnson & Johnson (JNJ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Lee ...

Project Stargate will see companies like Oracle, SoftBank, MGX, and OpenAI commit an initial $100 billion to build data ...

JNJ stock reporting earnings, expecting $2 EPS and $22.44B revenue, approval for Spravato, mixed chart signals, $167.71 price ...

Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.

Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ ...

Analysts on Wall Street project that Johnson & Johnson (JNJ) will announce quarterly earnings of $2 per share in its forthcoming report, representing a decline of 12.7% year over year. Revenues ...

La., recalled a meeting with President Biden from early last year during which the president appeared to forget he signed a ...

NEW YORK — Johnson & Johnson will spend more than $14 billion to delve further into the treatment of central nervous system disorders by purchasing Intra-Cellular Therapies. The health care giant said ...